What is Lixte Biotechnology Holdings Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Lixte Biotechnology Holdings Enterprise Value Chart
Competitive Comparison of Lixte Biotechnology Holdings's Enterprise Value
For the Biotechnology subindustry, Lixte Biotechnology Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's Enterprise Value falls into.
Lixte Biotechnology Holdings Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings (NAS:LIXT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Lixte Biotechnology Holdings's EV-to-EBIT for today is
Lixte Biotechnology Holdings's current Enterprise Value is $5.75 Mil.
Lixte Biotechnology Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.67 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Lixte Biotechnology Holdings's EV-to-EBITDA for today is:
Lixte Biotechnology Holdings's current Enterprise Value is $5.75 Mil.
Lixte Biotechnology Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.67 Mil.
Lixte Biotechnology Holdings's current Enterprise Value is $5.75 Mil.
Lixte Biotechnology Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings Enterprise Value Related Terms
Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIXT has been successfully added to your 